Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)
Brief Summary: To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Solifenacin 2.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron 25 mg, Mirabegron 50 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fesoterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fesoterodine fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fesoterodine fumarate; Assigned to Arm(s): Fesoterodine
C: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: fesoterodine fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Tolterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine tartrate | Intervention Type: DRUG; Name: fesoterodine fumarate; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: tolterodine tartrate; Assigned to Arm(s): Tolterodine
D: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine ER group; Type: EXPERIMENTAL; Interventions: Drug: tolterodine ER | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: DRUG; Name: tolterodine ER; Assigned to Arm(s): tolterodine ER group

Answer: C